Foresite Capital Management IV, LLC reported 5 positions worth $284.54M for the quarter ended Jun 30, 2026, up 20.0% on the prior quarter. It opened 0 new positions, added to 2, trimmed 0 and exited 3. Its largest holding is Pharvaris N.V. at 58.1% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No new positions this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHVS Pharvaris N.V. | Healthcare | 4.78M | $165.24M | 58.07% | 0 | 0.0% | Unchanged | 8.08% |
| 2 | CYTK Cytokinetics Inc | Healthcare | 714.7K | $60.88M | 21.4% | +211.4K | +42.0% | Added | 0.51% |
| 3 | EIKN Eikon Therapeutics, Inc. | Healthcare | 1.94M | $25.37M | 8.91% | 0 | 0.0% | Unchanged | 3.59% |
| 4 | RLAY Relay Therapeutics, Inc. | Healthcare | 1.25M | $23.39M | 8.22% | +250.0K | +25.0% | Added | 0.57% |
| 5 | XENE Xenon Pharmaceuticals Inc. | Healthcare | 160.0K | $9.66M | 3.39% | 0 | 0.0% | Unchanged | 0.16% |
Tip. Select a row to see that position’s full history at Foresite Capital Management IV.
As of its Q2 2026 13F filing, Foresite Capital Management IV, LLC’s five largest positions were Pharvaris N.V. (PHVS) at 58.1%, Cytokinetics Inc (CYTK) at 21.4%, Eikon Therapeutics, Inc. (EIKN) at 8.9%, Relay Therapeutics, Inc. (RLAY) at 8.2%, Xenon Pharmaceuticals Inc. (XENE) at 3.4% of the reported portfolio.
Foresite Capital Management IV, LLC reported a 13F portfolio worth $284.54M across 5 positions for Q2 2026. That is up 20.0% from the previous quarter.
Its largest purchases by value were Cytokinetics Inc ($18.01M), Relay Therapeutics, Inc. ($4.68M). It opened 0 new positions.
Its largest sales by value were Lyell Immunopharma, Inc. ($16.06M), Alector, Inc. ($8.36M), Maze Therapeutics, Inc. ($4.68M). It exited 3 positions entirely.
From the Form 13F-HR reports Foresite Capital Management IV, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.